| 摘要 |
A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1. |
| 申请人 |
REGENERON PHARMACEUTICALS, INC.;GLASS, DAVID, J.;YANCOPOULOS, GEORGE, D.;DALY, THOMAS, J.;PAPADOPOULOS, NICHOLAS, J. |
发明人 |
GLASS, DAVID, J.;YANCOPOULOS, GEORGE, D.;DALY, THOMAS, J.;PAPADOPOULOS, NICHOLAS, J. |
